Last reviewed · How we verify
NCT05490888
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Phase 1 trial testing PHIN-214 Subcutaneous injection in Cirrhosis, Liver in 74 participants. Currently enrolling.
31 May 2026
Quick facts
| Lead sponsor | PharmaIN |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 3 January 2022 |
| Primary completion | 31 May 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- PHIN-214 Subcutaneous injection — full drug profile →
Conditions studied
- Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
- Liver Fibrosis — all drugs for Liver Fibrosis →
- Ascites Hepatic — all drugs for Ascites Hepatic →
Sponsor
PharmaIN — full company profile →
Who can join
Adults 18 to 75, any sex, with Cirrhosis, Liver or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment of liver fibrosis: Past, current, and future.
Zhang CY, Liu S, Yang M. · · 2023 · cited 49× · PMID 37397931 · DOI 10.4254/wjh.v15.i6.755 -
Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist.
Castillo GM, Yao Y, Guerra RE, Jiang H, et al · · 2024 · cited 1× · PMID 38176129 · DOI 10.1016/j.biopha.2023.116068
Verify or expand the search:
- PubMed search for NCT05490888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cirrhosis, Liver
Currently open trials in the same condition.
- NCT07286643 — Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis · NA · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
- NCT07051369 — Frequency of Portal Hypertension Among Patient With Cirrhotic Liver With Ultrasound · active not recruiting
- NCT06908785 — Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05490888 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PharmaIN
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05490888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing